期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

蛋白酶体抑制剂联合表阿霉素杀伤肝癌细胞的研究

Cytotoxic Effect of Proteasome Inhibitor Combined With Epirubicin on HepG2 Cell Line
下载PDF
导出
摘要 目的观察蛋白酶体抑制剂MG132与表阿霉素(epirubicin,EPI)联合应用对人肝癌HepG2细胞系体外生长的影响。方法实验分为4组:空白对照组;1μg/mL EPI处理组;1μmol/L MG132处理组;1μmol/L MG132+1μg/mL EPI共同处理组。应用MTT法检测小剂量MG132与表阿霉素处理后对HepG2细胞的生长抑制作用,流式细胞术检测细胞凋亡。结果MTT法显示MG132与表阿霉素合用时对HepG2细胞的抑制率增加。流式细胞术测定显示对照组的HepG2细胞凋亡率为(0.87±0.19)%,1μmol/L MG132处理组细胞凋亡率为(5.53±0.99)%;1μg/mL EPI处理组细胞凋亡率为(13.8±1.37)%;1μmol/L MG132和1μg/mL EPI共处理组细胞凋亡率增加至(27.0±1.15)%。结论小剂量MG132与表阿霉素联合应用可增强致HepG2细胞凋亡作用。 Objective To observe the cytotoxic effect of proteasome Inhibitor MG132 combined with epirubicin （EPI） on human hepatocelluar cancer HepG2 cell line. Methods MTr was performed to evaluate the cytotoxic effect on HepG2 cell in MG132, EPI and combination group, respectively. HepG2 cell Apoptosis was detennined by flow cytometry analysis. Results The combination of MG132 with epirubicin effectively augmented the growth inhibition .Apoptotic rate for control group, lμmol/L MG132 group, 1μg/mL EPI group, and 1μmaol/L MG132 ＋ 1 μg/mL EPI group was （0.87 ± 0.19 ） %, （5.53 ± 0.99 ） %, （ 13.8 ± 1.37 ） %, （27.0 ± 1.15 ） %, respectively. Conclusion Low dose MG132 could enhance the cytotoxic effect of EPI on HepG2 celt.
作者 何慧 苏波 杨向东 郭芳 孙文清
机构地区 南华大学解剖学教研室 南华大学药理学教研室 南华大学病理生理学教研室
出处 《南华大学学报（医学版）》 2008年第1期36-38,共3页 Journal of Nanhua University(Medical Edition)
基金 湖南省教育厅项目(03C378)
关键词 蛋白酶体抑制剂 表阿霉素 肝癌细胞 凋亡 proteasome inhibitor epirubicin HepG2 cell apoptosis
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Rajkumar SV, Richardson PG, Hideshima T,et al. Proteasome inhibition as a novel therapeutic target in human cancer[J]. J Clin Oncol,2005,23(3) :630 - 639.
  • 2Emanuele S,Calvaruso G, Lauricella M, et al. Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl - XS and activation of caspase - 3[J]. Int J Oncol, 2002,21 (4) : 857 - 865.
  • 3Cervello M, annitrapani L, Rosa M, et al. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation specific carcase - dependent cleavage of beta - catenin and inhibition of beta - catenin - mediated transactivation[ J]. Int J Mol Med, 2004,3(5) : 741 - 748.
  • 4Wolff AC, Avidson NE. Primary systemic therapy in operable breast cancer[J]. J Clin Oncol,2000,18(7) : 1558 - 1569.
  • 5Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer [ J ]. Int J Cancer, 2001,93(4) :481 - 488.
  • 6Hochwald SN, Lind DS, Malaty J. Antineoplastic therapy in colorectal cancer through proteasome inhibition [ J ]. Am Surg, 2003,69 (1):15-23.
  • 7Guzman ML, Neering S J, Upchurch D, et al. Nuclear factor- kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[ J]. Blood,2001,98(8) :2301 - 2307.
  • 8Ishizawa J, Yoshida S, Oya M, et al. Inhibition of the ubiquitin - proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells[J]. J Oncol,2004,25(3):697 - 702.
  • 9Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication [ J ]. Annu Rev Pharmacol Toxicol, 2005,45 : 465 - 476.
  • 10HG Zhang, J Wang. Regulation of apoptosis proteins in cancer cells by ubiquitin[ J ]. Oncogene, 2004,23 ( 11 ) : 2009 - 2015.

二级参考文献20

  • 1金正均.合并用药中的相加[J].中国药理学报,1980,1:70-73.
  • 2SAMUELS B L. Management of recurrent desmoid tumor after surgery and radiation: role of cytotoxic and non-cytotoxic therapies[J]. Surg Oneol, 1999,8: 191-196.
  • 3KAYE S B, EISENHAUER E A, HAMILTON T C, et al. New noncytotoxic approaches to ovarian cancer [ J ]. Ann Oncol, 1999, 10(Suppl) : 165-168.
  • 4SAMONAKIS D N, MOSCHANDREAS J, ARNAOUTIS T, et al.Treatment of hepatocellular carcinoma with long acting somatostatin analogues[J]. Oncol Rep,2002,9:903-907.
  • 5SANO H,KAWAHIT Y,WILD R L,et al. Expression of cyclooxy-genase-1 and -2 in human colorectal cancer[J]. Cancer Res, 1995, 55 (17) : 3785-3789.
  • 6TSUJII M, KAWANO S, DUBOIS R N. Cyclooxygenase-expression in human colon cancer cells increases metastatic potential[J]. Proc Nail Acad Sci USA, 1997,94(7) :3336-3340.
  • 7SHENG H, SHAO J, MORROW J D, et al. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 [J]. Cancer Res, 1998,58 (2) : 362-366.
  • 8TODISCO A, SEVA C, TAKEUCHI Y, et al. Somatostatin inhibits AP-1 function via multiple protein phosphatases[ J ]. Am J Physiol, 1959.269: G160-G166.
  • 9DING M, DONG Z, CHEN F, et al. Asbestos induces activator protein-1 transactivation in transgenic mice[J]. Cancer Res, 1999, 59:1884-1889.
  • 10HUSSIN S S, SZABO I L,PAI R, et al. MAPK(ERK2) kinase: a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth[J]. Life Sci,2001,69:3045-3054.

共引文献6

南华大学学报（医学版）
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部